Esa Heinonen

1.5k total citations
27 papers, 1.0k citations indexed

About

Esa Heinonen is a scholar working on Cellular and Molecular Neuroscience, Neurology and Psychiatry and Mental health. According to data from OpenAlex, Esa Heinonen has authored 27 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 10 papers in Neurology and 5 papers in Psychiatry and Mental health. Recurrent topics in Esa Heinonen's work include Neurotransmitter Receptor Influence on Behavior (9 papers), Neuroscience and Neuropharmacology Research (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Esa Heinonen is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (9 papers), Neuroscience and Neuropharmacology Research (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Esa Heinonen collaborates with scholars based in Finland, United Kingdom and Sweden. Esa Heinonen's co-authors include Antti Haapalinna, Markku Anttila, Risto Lammintausta, V. V. Myllyl�, Antti Hervonen, Kari Antila, Pia Jaatinen, Kari Reinikainen, Iordanis Gravanis and Gabriele Reichmann and has published in prestigious journals such as Blood, Nature Biotechnology and Cancer.

In The Last Decade

Esa Heinonen

27 papers receiving 968 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Esa Heinonen Finland 18 248 240 186 160 135 27 1.0k
Jeremy D. Gale United States 23 139 0.6× 246 1.0× 32 0.2× 290 1.8× 125 0.9× 51 1.4k
Marco Ferrari Italy 25 500 2.0× 341 1.4× 193 1.0× 384 2.4× 210 1.6× 67 1.8k
Hideki Shuto Japan 19 91 0.4× 107 0.4× 88 0.5× 203 1.3× 126 0.9× 39 1.1k
Edward Tobinick United States 22 152 0.6× 201 0.8× 300 1.6× 420 2.6× 58 0.4× 30 1.7k
Domenico Italiano Italy 20 56 0.2× 179 0.7× 172 0.9× 174 1.1× 64 0.5× 43 1.1k
Aaron Y. Lai Canada 20 187 0.8× 385 1.6× 169 0.9× 342 2.1× 37 0.3× 37 1.6k
Jan Mareš Czechia 21 181 0.7× 160 0.7× 426 2.3× 203 1.3× 115 0.9× 60 1.4k
Luigi Francesco Iannone Italy 20 101 0.4× 134 0.6× 45 0.2× 288 1.8× 119 0.9× 73 1.1k
K J Zilkha United Kingdom 26 90 0.4× 149 0.6× 383 2.1× 286 1.8× 47 0.3× 55 1.7k

Countries citing papers authored by Esa Heinonen

Since Specialization
Citations

This map shows the geographic impact of Esa Heinonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esa Heinonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esa Heinonen more than expected).

Fields of papers citing papers by Esa Heinonen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esa Heinonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esa Heinonen. The network helps show where Esa Heinonen may publish in the future.

Co-authorship network of co-authors of Esa Heinonen

This figure shows the co-authorship network connecting the top 25 collaborators of Esa Heinonen. A scholar is included among the top collaborators of Esa Heinonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esa Heinonen. Esa Heinonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heinonen, Esa, et al.. (2018). A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA. Therapeutic Innovation & Regulatory Science. 53(1). 86–94. 5 indexed citations
2.
Schneider, Christian K., John-Joseph Borg, Falk Ehmann, et al.. (2012). Reply to In support of the European Union biosimilar framework. Nature Biotechnology. 30(8). 748–749. 4 indexed citations
3.
Haapalinna, Antti, Tiina Leino, & Esa Heinonen. (2003). The ?2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn-Schmiedeberg s Archives of Pharmacology. 368(5). 342–351. 31 indexed citations
4.
Anttila, Markku, et al.. (2000). Multiple-Dose Pharmacokinetics of Selegiline and Desmethylselegiline Suggest Saturable Tissue Binding. Clinical Neuropharmacology. 23(1). 22–27. 26 indexed citations
5.
Kilkku, Olavi, Esa Heinonen, Antti Helminen, et al.. (1999). The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers. Biopharmaceutics & Drug Disposition. 20(7). 327–334. 11 indexed citations
6.
Pirttilä, Tuula, Keijo Koivisto, Pankaj Mehta, et al.. (1998). Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neuroscience Letters. 249(1). 21–24. 27 indexed citations
7.
Heinonen, Esa & V. V. Myllyl�. (1998). Safety of Selegiline (Deprenyl) in the Treatment of Parkinson??s Disease. Drug Safety. 19(1). 11–22. 57 indexed citations
8.
Heinonen, Esa, Markku Anttila, Leena Nyman, et al.. (1997). Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans. The Journal of Clinical Pharmacology. 37(7). 602–609. 22 indexed citations
9.
Haapalinna, Antti, Timo Viitamaa, Ewen MacDonald, et al.. (1997). Evaluation of the effects of a specific α2-adrenoceptor antagonist, atipamezole, on α1- and α2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn-Schmiedeberg s Archives of Pharmacology. 356(5). 570–582. 79 indexed citations
10.
Jaatinen, Pia, et al.. (1997). Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat. Alcohol. 14(6). 537–544. 34 indexed citations
11.
Laine, Kari, Markku Anttila, Esa Heinonen, et al.. (1997). Lack of Adverse Interactions Between Concomitantly Administered Selegiline and Citalopram. Clinical Neuropharmacology. 20(5). 419–433. 46 indexed citations
12.
Heinonen, Esa, Markku Anttila, Leena Nyman, et al.. (1997). Inhibition of Platelet Monoamine Oxidase Type B by Selegiline. The Journal of Clinical Pharmacology. 37(7). 597–601. 7 indexed citations
13.
Salonen, Tapani, Antti Haapalinna, Esa Heinonen, Jaana Suhonen, & Antti Hervonen. (1996). Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathologica. 91(5). 466–474. 32 indexed citations
14.
Mäenpää, Juhani, Esa Heinonen, Susanna Hinkka‐Yli‐Salomäki, et al.. (1995). The Subrenal Capsule Assay in Selecting Chemotherapy for Ovarian Cancer: A Prospective Randomized Trial. Gynecologic Oncology. 57(3). 294–298. 26 indexed citations
15.
Jaatinen, Pia, et al.. (1995). Prevention of ethanol-induced sympathetic overactivity and degeneration by dexmedetomidine. Alcohol. 12(5). 439–446. 20 indexed citations
16.
Heinonen, Esa, Markku Anttila, & Risto Lammintausta. (1994). Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites*. Clinical Pharmacology & Therapeutics. 56(6 Pt 2). 742–749. 96 indexed citations
17.
Färkkilâ, Martti, et al.. (1990). Vibration Stress and the Autonomic Nervous System. The Kurume Medical Journal. 37(SUPPLEMENT). S53–S60. 13 indexed citations
18.
Persson, Lennart, et al.. (1990). Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine. Epilepsy Research. 6(2). 134–140. 34 indexed citations
19.
Hirvonen, Harri, et al.. (1989). Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer. 64(4). 801–805. 51 indexed citations
20.
Forsström, Jari, et al.. (1986). Effects of haemodialysis on heart rate variability in chronic renal failure. Scandinavian Journal of Clinical and Laboratory Investigation. 46(7). 665–670. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeremy D. Gale Breakdown of academic impact, for papers by Marco Ferrari Breakdown of academic impact, for papers by Hideki Shuto Breakdown of academic impact, for papers by Edward Tobinick Breakdown of academic impact, for papers by Domenico Italiano Breakdown of academic impact, for papers by Aaron Y. Lai Breakdown of academic impact, for papers by Jan Mareš Breakdown of academic impact, for papers by Luigi Francesco Iannone Breakdown of academic impact, for papers by K J Zilkha
Rankless by CCL
2026